dc.contributor.author | Menendez-Gutierrez, Maria Piedad | |
dc.contributor.author | Ricote, Mercedes | |
dc.date.accessioned | 2020-05-05T09:52:24Z | |
dc.date.available | 2020-05-05T09:52:24Z | |
dc.date.issued | 2017-06 | |
dc.identifier.citation | Cell Mol Life Sci. 2017; 74(12):2135-2149 | es_ES |
dc.identifier.issn | 1420-682X | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/9891 | |
dc.description.abstract | Retinoid X receptors (RXRs) form a unique subclass within the nuclear receptor (NR) superfamily of ligand-dependent transcription factors. RXRs are obligatory partners for a number of other NRs, placing RXRs in a coordinating role at the crossroads of multiple signaling pathways. In addition, RXRs can function as self-sufficient homodimers. Recent advances have revealed RXRs as novel regulators of osteoclastogenesis and bone remodeling. This review outlines the versatility of RXR action in the control of transcription of bone-forming osteoblasts and bone-resorbing osteoclasts, both through heterodimerization with other NRs and through RXR homodimerization. RXR signaling is currently a major therapeutic target and, therefore, knowledge of how RXR signaling affects bone remodeling creates enormous potential for the translation of basic research findings into successful clinical therapies to increase bone mass and improve bone quality. | es_ES |
dc.description.sponsorship | We thank S. Bartlett (CNIC) for editorial assistance. Some of the work reported in this review was supported by a grant from the Spanish Ministry of Economy and Competitiveness (SAF2015-64287) to M. Ricote. The CNIC is supported by the Spanish Ministry of Economy and Competitiveness (MINECO) and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (MINECO award SEV-2015-0505). We apologize to our many colleagues for not being able to cite all relevant references owing to space limitations. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Springer | es_ES |
dc.type.hasVersion | AM | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | 9-cis retinoic acid | es_ES |
dc.subject | Agonists | es_ES |
dc.subject | Antagonists | es_ES |
dc.subject | Bexarotene | es_ES |
dc.subject | Bone resorption | es_ES |
dc.subject | Heterodimers | es_ES |
dc.subject | Homodimers | es_ES |
dc.subject | MAFB | es_ES |
dc.subject | Osteoporosis | es_ES |
dc.subject | Permissive | es_ES |
dc.subject | Rexinoids | es_ES |
dc.subject | Skeleton | es_ES |
dc.subject.mesh | Animals | es_ES |
dc.subject.mesh | Bone Resorption | es_ES |
dc.subject.mesh | Humans | es_ES |
dc.subject.mesh | Models, Biological | es_ES |
dc.subject.mesh | Protein Multimerization | es_ES |
dc.subject.mesh | Retinoid X Receptors | es_ES |
dc.subject.mesh | Bone Remodeling | es_ES |
dc.title | The multi-faceted role of retinoid X receptor in bone remodeling | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.identifier.pubmedID | 28105491 | es_ES |
dc.format.volume | 74 | es_ES |
dc.format.number | 12 | es_ES |
dc.format.page | 2135-2149 | es_ES |
dc.identifier.doi | 10.1007/s00018-017-2458-4 | es_ES |
dc.contributor.funder | Ministerio de Economía y Competitividad (España) | |
dc.contributor.funder | Fundación ProCNIC | |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 1420-9071 | es_ES |
dc.relation.publisherversion | https://doi.org/10.1007/s00018-017-2458-4 | es_ES |
dc.identifier.journal | Cellular and molecular life sciences : CMLS | es_ES |
dc.repisalud.orgCNIC | CNIC::Grupos de investigación::Señalización de los Receptores Nucleares | es_ES |
dc.repisalud.institucion | CNIC | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/SEV-2015-0505 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/SAF2015-64287 | es_ES |
dc.rights.accessRights | open access | es_ES |